Patients with low tumor PD-L2 levels (HR 1.59, 95% CI 1.206–2.106, p = 0.001) presented an increased risk for poor OS after adjustment for sex, age, pT stage, pN stage, pTNM stage, LVI, PNI, tumor location and immune signatures. The gene discussed is PDCD1LG2; the disease is neoplasm.